Table 1 Baseline characteristics of the study participants
From: Telomere attrition in heart failure: a flow-FISH longitudinal analysis of circulating monocytes
n = 101 | |
|---|---|
Age (years) | 65.6 ± 11.3 |
Male sex | 76 (75.2%) |
Etiology | |
Ischemic heart disease | 46 (45.5%) |
Dilated cardiomyopathy | 18 (17.8%) |
Hypertensive cardiomyopathy | 8 (7.9%) |
Alcoholic cardiomyopathy | 7 (6.9%) |
Valvular disease | 8 (7.9%) |
Hypertrophic cardiomyopathy | 4 (4.0%) |
Other | 10 (9.9%) |
HF duration in months | 38.7 (12.7–77.4) |
LVEF | 41.8% ± 12.1 |
NYHA functional class | |
I | 9 (8.9%) |
II | 70 (69.3%) |
III | 22 (21.8%) |
Co-morbidities | |
Hypertension | 74 (73.3%) |
Diabetes mellitus | 50 (49.5%) |
Renal failurea | 48 (47.5%) |
Anemiab | 41 (40.6%) |
Atrial fibrillation/flutter | 42 (41.6%) |
Obesity | 31 (30.7%) |
Smoker | |
Current | 4 (4.0%) |
Past | 66 (65.3%) |
Treatments | |
ACEI/ARB | 89 (88.1%) |
Beta-blockers | 93 (92.1%) |
MRA | 63 (62.4%) |
Loop diuretics | 81 (80.2%) |
Digoxin | 21 (20.8%) |
Ivabradine | 19 (18.8%) |
Statins | 86 (85.1%) |
ICD | 3 (3.0%) |
CRT | 16 (15.8%) |